{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:31:25Z","timestamp":1761489085000,"version":"3.44.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":3313,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","fertstert.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Fertility and Sterility"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.fertnstert.2013.01.105","type":"journal-article","created":{"date-parts":[[2013,2,15]],"date-time":"2013-02-15T18:31:00Z","timestamp":1360953060000},"page":"1786-1790","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Faster thrombin generation in women with polycystic ovary syndrome compared with healthy controls matched for age and body mass index"],"prefix":"10.1016","volume":"99","author":[{"given":"Maria Raquel Marques Furtado de","family":"Mendon\u00e7a-Louzeiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce Maria","family":"Annichino-Bizzacchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu\u00eds Alberto","family":"Magna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan Kelly Picoli","family":"Quaino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina Laguna","family":"Benetti-Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.fertnstert.2013.01.105_bib1","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1210\/jc.2003-032046","article-title":"The prevalence of polycystic ovary syndrome among unselected consecutive premenopausal women","volume":"89","author":"Azziz","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/bmj.293.6543.355","article-title":"Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism","volume":"293","author":"Adams","year":"1986","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib3","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1210\/jc.2006-0178","article-title":"Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline","volume":"91","author":"Azziz","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib4","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.5694\/mja11.10915","article-title":"Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline","volume":"195","author":"Teede","year":"2011","journal-title":"Med J Aust"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib5","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1210\/jc.2009-2724","article-title":"Assessment of cardiovascular risk and prevention of cardiovascular disease in women with polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society","volume":"95","author":"Wild","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib6","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0015-0282(99)00468-9","article-title":"Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity","volume":"73","author":"Mather","year":"2000","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib7","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.fertnstert.2007.03.081","article-title":"Prevalence of the metabolic syndrome and its components in Brazilian women with polycystic ovary syndrome","volume":"89","author":"Soares","year":"2008","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.fertnstert.2011.09.024","article-title":"Consensus on women\u2019s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE\/ASRM-Sponsored 3rd PCOS Consensus Workshop Group","volume":"97","author":"Fauser","year":"2012","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib9","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.fertnstert.2008.06.035","article-title":"The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report","volume":"91","author":"Azziz","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib10","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJM199503093321003","article-title":"Hemostatic factors and risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group","volume":"332","author":"Thompson","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib11","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0015-0282(16)56575-3","article-title":"Hemostatic and metabolic variables in women with polycystic ovary syndrome","volume":"61","author":"Dahlgren","year":"1994","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib12","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S0015-0282(97)00486-X","article-title":"The plasminogen activator system in women with polycystic ovary syndrome","volume":"69","author":"Atiomo","year":"1998","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib13","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1046\/j.1365-2265.2000.00946.x","article-title":"Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS)","volume":"52","author":"Atiomo","year":"2000","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib14","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1055\/s-0029-1242715","article-title":"Polycystic ovarian syndrome and the risk of cardiovascular disease and thrombosis","volume":"35","author":"Mak","year":"2009","journal-title":"Semin Thromb Haemost"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib15","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1055\/s-0029-1242712","article-title":"Coagulopathies and thrombosis: usual and unusual causes and associations, part II","volume":"35","author":"Lippi","year":"2009","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib16","first-page":"83","article-title":"Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women","volume":"10","author":"Alexander","year":"2009","journal-title":"Rev Cardiov Med"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib17","series-title":"Laboratory techniques in thrombosis\u2014a manual","first-page":"63","article-title":"Endogenous thrombin potential","author":"Hemker","year":"1999"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0038-1661594","article-title":"A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes","volume":"56","author":"Hemker","year":"1986","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000071636","article-title":"Calibrated automated thrombin generation measurement in clotting plasma","volume":"33","author":"Hemker","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib20","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/j.1538-7836.2005.01388.x","article-title":"A new functional assay of thrombin activatable fibrinolysis inhibitor","volume":"3","author":"Guimar\u00e3es","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib21","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/j.1538-7836.2007.02430.x","article-title":"TAFIa, PAI-1 and alpha2-antiplasmin: complementary roles in regulating lysis of thrombin and plasma clots","volume":"5","author":"Mutch","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib22","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1161\/01.ATV.20.12.2511","article-title":"Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway","volume":"20","author":"Bajzar","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib23","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1182\/blood.V95.9.2855.009k02_2855_2859","article-title":"Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis","volume":"95","author":"Van Tilburg","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib24","doi-asserted-by":"crossref","first-page":"229","DOI":"10.11606\/issn.2176-7262.v34i3\/4p229-237","article-title":"Overview of coagulation, anticoagulation and fibrinolysis","volume":"34","author":"Franco","year":"2001","journal-title":"Medicina Ribeir\u00e3o Preto"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib25","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/j.1538-7836.2007.02396.x","article-title":"Influence of the Thr325Ile polymorphism on procarboxypeptidase U (thrombin-activatable fibrinolysis inhibitor) activity-based assays","volume":"5","author":"Willemse","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib26","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00404-008-0884-0","article-title":"High mean platelet volume, low-grade systemic coagulation and fibrinolytic activation are associated with androgen and insulin levels in polycystic ovary syndrome","volume":"280","author":"Kebapcilar","year":"2009","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib27","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1161\/01.CIR.94.9.2057","article-title":"Fibrinolytic factors and the risk of miocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities","volume":"94","author":"Juhan-Vague","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib28","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1111\/j.1538-7836.2005.01420.x","article-title":"PAI-1 and atherothrombosis","volume":"3","author":"Vaughan","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.fertnstert.2003.10.004","article-title":"Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome","volume":"81","year":"2004","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib30","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1210\/jcem-21-11-1440","article-title":"Clinical assessment of body hair growth in women","volume":"21","author":"Ferriman","year":"1961","journal-title":"J Clin Endocrinol"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib31","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.fertnstert.2004.11.070","article-title":"Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment","volume":"83","author":"De Ugarte","year":"2005","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib32","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1160\/TH07-03-0210","article-title":"Thrombin generation in plasma of healthy adults and children: chromogenic versus fluorogenic thrombogram analysis","volume":"98","author":"Devreese","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib33","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/09513590802549874","article-title":"Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome","volume":"25","author":"Oral","year":"2009","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib34","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1055\/s-2007-992118","article-title":"Thrombin-activatable fibrinolysis inhibitor and cardiovascular risk factors in polycystic ovary syndrome","volume":"16","author":"Erdogan","year":"2008","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib35","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/09513590802291824","article-title":"Increased thrombin-activatable fibrinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome","volume":"24","author":"Karakurt","year":"2008","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib36","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1365-2141.2004.04824.x","article-title":"Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays","volume":"124","author":"Guimar\u00e3es","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib37","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/j.1538-7836.2005.01486.x","article-title":"TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME study","volume":"3","author":"Morange","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib38","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1210\/jc.2010-2279","article-title":"Coagulation and fibrinolytic disturbances in women with polycystic ovary syndrome","volume":"96","author":"Manner\u00e2s-Holm","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib39","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/jcem.87.8.8716","article-title":"Global fibrinolytic system is decreased in polycystic ovary syndrome, suggesting a prothrombotic state","volume":"87","author":"Yildiz","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib40","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.thromres.2004.11.026","article-title":"Insulin resistance causes impaired vasodilatation and hypofibrinolysis in young women with polycystic ovary syndrome","volume":"116","author":"Carmassi","year":"2005","journal-title":"Thromb Res"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib41","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.tcm.2012.01.001","article-title":"Hemostatic abnormalities and relationships to metabolic and hormonal status in polycystic ovarian syndrome","volume":"21","author":"Burchall","year":"2011","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib42","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/09513590601005805","article-title":"Comparison of fibrinolytic and metabolic system parameters in obese patients with polycystic ovary syndrome and woman with simple obesity","volume":"22","author":"Slopien","year":"2006","journal-title":"Ginecol Endocrinol"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib43","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.atherosclerosis.2004.12.031","article-title":"The metabolic syndrome and insulin resistance: relationship to haemostatic and inflammatory markers in older non-diabetic men","volume":"181","author":"Wannamethee","year":"2005","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib44","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1210\/jcem.87.7.8634","article-title":"A specific elevation in tissue plasminogen activator antigen in women with polycystic ovarian syndrome","volume":"87","author":"Kelly","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib45","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.diabres.2005.12.008","article-title":"Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type-2 diabetic patients","volume":"73","author":"Kitagawa","year":"2006","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib46","series-title":"Thrombosis and hemorrhage","first-page":"3","article-title":"Coagulation cascade: an overview","author":"Jenny","year":"1998"},{"key":"10.1016\/j.fertnstert.2013.01.105_bib47","series-title":"Hemostasis and thrombosis. Basic principles and clinical practice","first-page":"3","article-title":"Overview of hemostasis","author":"Colman","year":"2001"}],"container-title":["Fertility and Sterility"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0015028213001611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0015028213001611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T08:04:50Z","timestamp":1758009890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0015028213001611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0015028213001611"],"URL":"https:\/\/doi.org\/10.1016\/j.fertnstert.2013.01.105","relation":{},"ISSN":["0015-0282"],"issn-type":[{"type":"print","value":"0015-0282"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Faster thrombin generation in women with polycystic ovary syndrome compared with healthy controls matched for age and body mass index","name":"articletitle","label":"Article Title"},{"value":"Fertility and Sterility","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fertnstert.2013.01.105","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}